Fundraising FoxPresidio Pharmaceuticals
San Francisco, US · 2 known investors
Find your way into Presidio Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
26 people can intro you to Nathaniel
Ask Ryan Wetzel to introduce you to Nathaniel Brown
You →Ryan · together at Idenix Pharmaceuticals →Nathaniel
Sign up to find every way you can get introduced to Presidio Pharmaceuticals
- Your email: who you already know at Presidio Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Presidio Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
PV
Pamela VigExecutive
RC
Richard ColonnoExecutive
NB
Nathaniel BrownChief Medical Officer and Sr VP, Clinical DevelopmentHe brings two decades of clinical development experience in antiviral medicines, including former leadership of hepatitis drug development at GlaxoWellcome/GSK, and has contributed to multiple antiviral product registrations across North America, Europe, and Asia.
ER
Eric RubyExecutive
Board
RW
Robert WilliamsonBoard director
HD
H. Daniel PerezBoard director
SL
Scott LessingBoard director
OH
Omar HaffarBoard director
Investors · 2
Bay City CapitalreportedSan Rafael · $5M – $10M
How we know: funding news · Not right? Tell us
New Leaf Venture PartnersreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$21.8M disclosed across 1 round · 2013
▶$21.8MraisedJun 2014 · 16 investors · PharmaceuticalsRule 506(b)
▶$21.8MraisedJun 2014 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert WilliamsonDirector
- Pamela VigExecutive Officer
- Richard ColonnoExecutive Officer
- Nathaniel BrownExecutive Officer
- Eric RubyExecutive Officer
- Scott LessingDirector
- Leping LiExecutive Officer
- H. Daniel PerezDirector
- Leo RedmondExecutive Officer, Director
- Omar HaffarDirector
- Offering amount
- $22.5M
- Amount sold
- $21.8M
- Proceeds to insiders
- $1M
- First sale
- Apr 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Presidio Pharmaceuticals's investors?
- Presidio Pharmaceuticals's investors include Bay City Capital, New Leaf Venture Partners.
- How much funding has Presidio Pharmaceuticals raised?
- Presidio Pharmaceuticals has disclosed $21.8M raised across 1 round.
- Where is Presidio Pharmaceuticals headquartered?
- Presidio Pharmaceuticals is headquartered in San Francisco, US.